XML 46 R13.htm IDEA: XBRL DOCUMENT
v3.20.2

Intangible Assets and Goodwill | 6 Months Ended
--- | ---
Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets and Goodwill | Intangible Assets Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:
|  |  | As of June 30, 2020 |  | As of December 31, 2019
(In millions) | Estimated Life |  | Cost |  | Accumulated Amortization |  | Net |  | Cost |  | Accumulated Amortization |  | Net
Completed technology | 4-28 years |  | $ | 7,379.3 |  |  | $ | (5,014.4 | ) |  | $ | 2,364.9 |  |  | $ | 7,379.3 |  |  | $ | (4,881.4 | ) |  | $ | 2,497.9 |
In-process research and development | Indefinite until commercialization |  | 954.9 |  |  | — |  |  | 954.9 |  |  | 965.5 |  |  | — |  |  | 965.5 |
Trademarks and trade names | Indefinite |  | 64.0 |  |  | — |  |  | 64.0 |  |  | 64.0 |  |  | — |  |  | 64.0 |
Total intangible assets |  |  | $ | 8,398.2 |  |  | $ | (5,014.4 | ) |  | $ | 3,383.8 |  |  | $ | 8,408.8 |  |  | $ | (4,881.4 | ) |  | $ | 3,527.4 |
For the three and six months ended June 30, 2020, amortization and impairment of acquired intangible assets totaled $61.5 million and $133.0 million, respectively, compared to $70.1 million and $138.3 million, respectively, in the prior year comparative periods. We had no impairment charges for the three and six months ended June 30, 2020 and 2019. Completed Technology Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc, and milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in October 2019, net of accumulated amortization. IPR&D Related to Business Combinations IPR&D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&D assets as of June 30, 2020, relates to the various IPR&D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&D programs with an estimated fair value of approximately $700.0 million. Vixotrigine In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. The fair value of the TGN asset is not significantly in excess of carrying value. As of June 30, 2020, the carrying value associated with our vixotrigine IPR&D assets was $160.2 million. Estimated Future Amortization of Intangible Assets The estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:
(In millions) |  | As of June 30, 2020
2020 (remaining six months) |  | $ | 126.0 |
2021 |  | 220.0 |
2022 |  | 220.0 |
2023 |  | 230.0 |
2024 |  | 230.0 |
2025 |  | 220.0 |
Goodwill The following table provides a roll forward of the changes in our goodwill balance:
(In millions) |  | As of June 30, 2020
Goodwill, beginning of period |  | $ | 5,757.8 |
Other |  | (6.8 | )
Goodwill, end of period |  | $ | 5,751.0 |
As of June 30, 2020, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration